{
    "2019-03-28": [
        [
            {
                "time": "2020-01-01",
                "original_text": "疫苗行业喜报频传，业绩下降仅一家，最高涨幅达600% 盈利能力下降",
                "features": {
                    "keywords": [
                        "疫苗行业",
                        "喜报频传",
                        "业绩下降",
                        "最高涨幅",
                        "盈利能力下降"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药",
                        "疫苗"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2020-01-01",
                "original_text": "生物制品-创新疫苗大产品大时代将进入第二波大浪潮，板块迎来布局良机【国盛医药张金洋团队】",
                "features": {
                    "keywords": [
                        "生物制品",
                        "创新疫苗",
                        "大产品",
                        "第二波大浪潮",
                        "布局良机"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药",
                        "疫苗"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            }
        ]
    ]
}